Medicus Pharma Receives FDA Clearance for SkinJect Phase 2b Study

Key Facts

In a move reflecting regulatory progress in the biotechnology sector, Medicus Pharma has received a 'Study May Proceed' letter from the U.S. Food and Drug Administration (FDA) to begin its Phase 2b registrational study of SkinJect. This study targets patients with Gorlin syndrome who develop multiple basal cell carcinomas. The authorization follows the FDA's review of the company's Investigational New Drug (IND) application and subsequent responses to agency information requests.

The upcoming study builds on encouraging historical data, as previous Phase 1 and Phase 2 trials reportedly showed a favorable safety profile and positive clinical clearance rates. According to the clinical plans, the Phase 2b open-label study will evaluate SkinJect 200 micrograms in up to 50 patients across multiple centers. The FDA has provided additional recommendations, including the establishment of an independent Data Safety Monitoring Board and refined statistical methods to strengthen the registrational data package.

Operationally, this clearance marks a significant milestone for the SkinJect program as it advances toward a potential New Drug Application (NDA) submission. Market participants are monitoring broader economic indicators, such as the U.S. Leading Index which recently stood at -0.2%, to gauge the investment appetite for micro-cap clinical-stage biotech firms.